Mizoribine

Drug Profile

Mizoribine

Alternative Names: Bredinin; HE-69

Latest Information Update: 06 Feb 2017

Price : $50

At a glance

  • Originator Asahi Kasei
  • Developer Asahi Kasei; Asahi Kasei Pharma Corp; Chong Kun Dang
  • Class Antirheumatics; Ribonucleosides; Small molecules
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lupus nephritis; Nephrotic syndrome; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 06 Feb 2017 Mizoribine is still in phase III trials for Nephrotic syndrome (Treatment-resistant) and Lupus nephritis in China (PO)
  • 01 Nov 2014 Phase-III clinical trials in Lupus nephritis in China (PO) (NCT02256150)
  • 01 Nov 2014 Phase-III clinical trials in Nephrotic syndrome (Treatment-resistant) in China (PO) (NCT02257697)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top